Clinical Trials Logo

Neoplasms clinical trials

View clinical trials related to Neoplasms.

Filter by:

NCT ID: NCT04950608 Active, not recruiting - Clinical trials for Cancer-related Problem/Condition

Pilot Study of Psilocybin-Assisted Therapy for Demoralization in Patients Receiving Hospice Care

PATH
Start date: March 9, 2022
Phase: Phase 2
Study type: Interventional

The overall objective of this study is to develop and pilot test a novel regimen of psilocybin-assisted psychotherapy for demoralization in patients receiving hospice care. -The name of the study drug involved in this study is Psilocybin

NCT ID: NCT04950140 Not yet recruiting - Oncology Clinical Trials

Randomized Clinical Trial Comparing Conventional Laparoscopic Surgery and Robot-Assisted Laparoscopic Surgery for the Treatment of Parastomal Hernia of the Oncology Patient

LAROPA
Start date: July 24, 2021
Phase: N/A
Study type: Interventional

Prospective randomized prospective interventional study with 40 consecutive patients for whom surgical treatment for PH was indicated and who are in postoperative follow-up with the Oncology Surgery group of the Department of Digestive Tract Surgery and Coloproctology, Faculty of Medicine, University of São Paulo . The free and informed consent form will be applied to the patient by the researchers in two copies of equal content and after any doubts related to the research are resolved, the patient will sign the copies together with the researcher. At any time, the patient may opt out of the study. The contacts of the researchers and the institution will be fully available to the research subject to resolve doubts and for any eventuality that may occur.

NCT ID: NCT04949737 Not yet recruiting - Stomach Neoplasms Clinical Trials

Prevalence of Helicobacter Pylori Infection and Gastric Cancer in the West Indies

Hélico-MQ
Start date: April 2024
Phase:
Study type: Observational

Estimating the prevalence of Helicobacter Pylori infection in newly diagnosed stomach cancers in the West-Indies will help to understand the epidemiology of this cancer, which is over-incident in the West Indies compared to France. In addition, the constitution of a biobank (tumor tissues, healthy tissues and serum) will allow to set up in a second time etiological studies to identify other risk factors in particular in connection with the exposure to environmental pollutants to adapt the prevention measures.

NCT ID: NCT04949425 Terminated - Clinical trials for Advanced Solid Tumours

A Study to Assess the Safety and Tolerability of Adavosertib for Patients With Advanced Solid Tumours

Start date: September 13, 2021
Phase: Phase 1
Study type: Interventional

The purpose of this study is to allow continued adavosertib treatment of patients with advanced solid tumours participating in the adavosertib clinical pharmacology studies and to assess the continued safety and tolerability of adavosertib for patients enrolled in adavosertib clinical pharmacology studies (hereafter referred to as the 'parent studies') who continue to use the therapy

NCT ID: NCT04949282 Recruiting - Neoplasms Clinical Trials

Spanish Series of Patients Treated With the Radionuclide Lutetium177

SEPTRALU
Start date: May 10, 2021
Phase:
Study type: Observational

This study aims to pool the clinical experience of Spanish centers treating patients with 177Lu-DOTATATE to evaluate the efficacy, tolerance, and safety of the drug in routine clinical practice and to learn about the profiles of patients and tumors treated and the results in each type of patient and tumor.

NCT ID: NCT04949191 Terminated - Clinical trials for Advanced Malignancies

The Purpose of the Study is to Continue to Provide Pemigatinib to Patients With Advanced Malignancies.

Start date: July 8, 2021
Phase: Phase 2
Study type: Interventional

Safety and tolerability of pemigatinib.in monotherapy or combination in patients that have participated in a previous parent study to treat advanced malignancies.

NCT ID: NCT04948762 Recruiting - Clinical trials for Locally Advanced Rectal Cancer

A Contemporary Review of Surgical Approaches in Pelvic Exenterative Surgery

Start date: August 1, 2021
Phase:
Study type: Observational

Minimally-invasive surgery (MIS) techniques have revolutionised the approach to rectal cancer surgery. With increasing experience, surgeons have began to utilise these platforms increasingly in the context of pelvic exenteration (PE). This observational retrospective review plans to assess the volume of PE being performed on a global basis and to assess the comparative outcomes associated with each technique in order to assess the optimal approach to radical pelvic surgery.

NCT ID: NCT04947033 Recruiting - Clinical trials for Advanced Solid Tumor

A Study Evaluating TJ210001 in the Treatment of Subjects With Advanced Solid Tumors

Start date: December 31, 2023
Phase: Phase 1
Study type: Interventional

A phase I clinical study evaluating TJ210001 in the treatment of subjects with advanced solid tumors

NCT ID: NCT04945928 Active, not recruiting - Advanced Cancer Clinical Trials

Safety and Feasibility of Surgery After Conversion Therapy for Locally Advanced and Advanced NSCLC

Start date: August 27, 2021
Phase: N/A
Study type: Interventional

Lung cancer is one of the most common malignant tumors worldwide and the mortality ranks first in the world. In recent years, with the development of targeted therapy and immunotherapy, the overall survival of lung cancer patients has improved significantly. However, the inoperable advanced tumor remains the main reason for the poor prognosis of lung cancer. Thus, we aim to carry out this single-arm, prospective study to evaluate the safety and feasibility of surgery after conversion therapy for locally advanced and advanced non-small cell lung cancer.

NCT ID: NCT04945733 Terminated - Stomach Neoplasms Clinical Trials

A Study of Amivantamab in Participants With Previously Treated Advanced or Metastatic Gastric or Esophageal Cancer

Start date: August 30, 2021
Phase: Phase 2
Study type: Interventional

The purpose of this study is to investigate the activity of amivantamab in gastric cancer (GC) and esophageal cancer (EC) participants (Phase 2a), and to characterize the preliminary antitumor activity of amivantamab in selected GC and EC population (Phase 2b).